Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

Abstract

The detection of persistent leukemia-associated mutations in at least 5% of bone marrow cells in day 30 remission samples was associated with a significantly increased risk of relapse, and reduced overall survival. These data suggest that this genomic approach may improve risk stratification for patients with AML.